Overview
Jonathan Barthelet is a Hospital Medicine provider in Santa Monica, California. Dr. Barthelet is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Spontaneous Coronary Artery Dissection (SCAD), Heart Failure with Preserved Ejection Fraction (HFpEF), and Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
His clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- INSURANCE PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
Accepted plan types not found. Please verify directly with the provider.
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- PPO
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2121 Wilshire Blvd, Suite 304, Santa Monica, CA 90403
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
City Of Hope Medical Foundation
Haris Ali is a Hematologist and a Hematologist Oncology provider in Newport Beach, California. Dr. Ali is rated as an Elite provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Myelofibrosis, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Aspiration, and Bone Marrow Transplant.
City Of Hope Medical Foundation
Michael Zourabian is a Hospital Medicine provider in South Pasadena, California. Dr. Zourabian is rated as an Advanced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Febrile Neutropenia, ALK-Positive Non-Small Cell Lung Cancer, Relapsed Refractory Multiple Myeloma (RRMM), Inappropriate Sinus Tachycardia (IST), and Bone Marrow Aspiration.
City Of Hope Medical Foundation
Scott Goldsmith is a Hematologist and a Hospital Medicine provider in South Pasadena, California. Dr. Goldsmith is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Spontaneous Coronary Artery Dissection (SCAD)
- Experienced
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)